Summary

Eligibility
for people ages 18-100 (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around
Principal Investigator
by Pamela Munster
Headshot of Pamela Munster
Pamela Munster

Description

Summary

The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.

The primary objective of Part 3 of this study is to evaluate the efficacy of AMG 193 in adult participants with metastatic or locally advanced MTAP-null solid tumors.

Official Title

A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors

Keywords

Advanced MTAP-null Solid Tumors, Metastatic MTAP-null solid tumors, Non-small cell lung cancer, Biliary Tract Cancer (BTC), Head and neck squamous cell carcinoma, Pancreatic adenocarcinoma, Esophageal cancer, Gastric cancer, Glioma, Neoplasms, Docetaxel, AMG 193, Comparator AMG 193 Test Tablet

Eligibility

Locations

  • University of California at SF accepting new patients
    San Francisco California 94158 United States
  • Fomat Medical Research terminated
    Oxnard California 93030 United States
  • California Research Institute accepting new patients
    Glendale California 91204 United States

Lead Scientist at UCSF

  • Pamela Munster
    Professor, Medicine, School of Medicine. Authored (or co-authored) 161 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Amgen
Links
AmgenTrials clinical trials website
ID
NCT05094336
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
Expecting 649 study participants
Last Updated